Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
Dr Crescent Moore Outlines Part D Changes to Expect in 2020
March 27, 2019
The Balancing Act of Using Pharmacy Strategies to Fight the Opioid Epidemic
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Dr Michael Steinman Discusses Effective Strategies for Improving Medication Management
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Currently Reading
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Crescent Moore on Implementing Care Coordination Programs in Medicare
April 25, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019

Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations

CMS has given plan sponsors the flexibility to choose which drug therapy categories they’d like to administer the Part B step on, explained Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors,


CMS has given plan sponsors the flexibility to choose which drug therapy categories they’d like to administer the Part B step on, explained Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors,

Transcript

CMS is proposing allowing step therapy in Medicare Advantage plans for Part B drugs. Which drugs will this impact, and how will patients be affected?

The beauty of it all is that CMS really has given plan sponsors flexibility to choose which drug therapy categories they’d like to administer the Part B step on, and ideally, when you start thinking about good candidates to be a part of a step therapy, you want to look at drug therapy categories that have quite a few agents in them that have similar efficacy to really help you to be able to decide where can you really kick this off. I think the other thing to take into consideration is that plans are still going to be held by those local coverage determinations and national coverage determinations, so they do need to keep that in mind.

But, if I have to use my crystal ball and think about what might be a good therapeutic category, obviously the biosimilars and those classes that have those. So, thinking about the erythropoietin agents, as well as the infliximab products. And then another one might be even the hyaluronic acid agents because of the fact that there are just so many in that class, and really from a clinical perspective, they have very similar effectiveness.

Do you think the different formulary regulations proposed by CMS will help lower drug costs?

My ideal answer, I would love to see it help lower drug costs. I think that there are still some unknowns in terms of the safe harbor rule that was recently released and what is that going to do for the industry in respect to rebates and how those dollars get redistributed. I think the other thing that we are going to have to realize is that no one is mandated to do an indication-based formulary or to do a Part B step. So, if we don’t have widespread uptake by plan sponsors of these programs, I think that the benefit that we’d like to see might not be as large as we’d hope.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up